iBio, Inc. (IBIO) Monday reported encouraging data from a non-GLP non-human primate (NHP) pharmacokinetics study of the company's lead drug candidate IBIO-600 for the treatment of obesity. The study was designed to evaluate the potential of IBIO-600 in NHPs by determining the antibody's half-life in serum and analyzing changes in lean and fat mass. Data from the study suggests that IBIO-600 could have a human half-life as long as 130 days. Further, IBIO-600 promoted a dose-dependent increase in lean mass and a reduction in fat mass from baseline values.
iBio is on track for a regulatory submission for IBIO-600 in the first quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.